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Abstract
The protein a-synuclein is involved in the pathogenesis of Parkinson’s disease and other neurodegenerative disorders. Its
toxic potential appears to be enhanced by increased protein expression, providing a compelling rationale for therapeutic
strategies aimed at reducing neuronal a-synuclein burden. Here, feasibility and safety of a-synuclein suppression were
evaluated by treating monkeys with small interfering RNA (siRNA) directed against a-synuclein. The siRNA molecule was
chemically modified to prevent degradation by exo- and endonucleases and directly infused into the left substantia nigra.
Results compared levels of a-synuclein mRNA and protein in the infused (left) vs. untreated (right) hemisphere and revealed
a significant 40–50% suppression of a-synuclein expression. These findings could not be attributable to non-specific effects
of siRNA infusion since treatment of a separate set of animals with luciferase-targeting siRNA produced no changes in a-
synuclein. Infusion with a-synuclein siRNA, while lowering a-synuclein expression, had no overt adverse consequences. In
particular, it did not cause tissue inflammation and did not change (i) the number and phenotype of nigral dopaminergic
neurons, and (ii) the concentrations of striatal dopamine and its metabolites. The data represent the first evidence of
successful anti-a-synuclein intervention in the primate substantia nigra and support further development of RNA
interference-based therapeutics.
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Introduction
Several lines of evidence link the protein a-synuclein to human
neurodegenerative diseases. Point mutations in the a-synuclein
gene (SNCA) and increased expression of wild-type a-synuclein due
to SNCA multiplication mutations are causally associated with
familial forms of parkinsonism and dementia [1–5]. a-Synuclein is
also implicated in the pathogenesis of non-familial diseases such as
idiopathic Parkinson’s disease (PD), dementia with Lewy bodies
(DLB) and multiple system atrophy (MSA). In PD and DLB, a-
synuclein is a major component of the intraneuronal inclusions
called Lewy bodies and Lewy neurites that accumulate extensively
throughout the brain and have been suggested to underlie disease
development and progression [6,7]. A widespread diffusion of
oligodendroglial cytoplasmic inclusions composed of filamentous
a-synuclein is observed in MSA and has recently been proposed as
a criterion for definite post-mortem disease diagnosis [8,9]. The
tendency of a-synuclein to aggregate, which is well documented
by both in vitro and in vivo experimental work, likely explains the
formation of these neuronal and glial pathologic inclusions [10–
12]. It may also result in a gain of toxic function of the protein and
therefore contribute to neuronal injury and degeneration [10–13].
The toxic properties of a-synuclein together with its involve-
ment in pathogenetic processes point to this protein as a promising
target for new therapeutic intervention against PD and other a-
synuclein-related neurodegenerative disorders (collectively referred
to as a-synucleinopathies) [14]. Because clinical and experimental
findings indicate that higher levels of a-synuclein promote its toxic
potential [3,11–13], it is also reasonable to postulate that
neuroprotective effects could be achieved by suppressing neuronal
expression of the protein. RNA interference (RNAi) is a pathway
of post-transcriptional gene silencing that, since its characteriza-
tion in the late 1990s, has given researchers the opportunity to
study the consequences of selective gene knockdown experimen-
tally. As importantly, exploitation of this pathway has been
proposed for the treatment of diseases that feature the expression
of specific harmful proteins; based on the previous considerations,
it is not surprising that a-synucleinopathies are often listed among
these diseases [15].
Earlier investigations have tested RNA molecules targeting a-
synuclein via RNAi in neuron-like cell cultures as well as in rodent
models in vivo [16–19]. In the latter, short hairpin (sh) a-synuclein
RNA delivered via a lentiviral vector was found to silence ectopic
expression of human a-synuclein in the rat striatum, and small
interfering RNA (siRNA) directed against a-synuclein reduced the
expression of endogenous a-synuclein after a two-week infusion
into the mouse hippocampus [17,18]. No signs of toxicity were
reported as a consequence of these treatments. More recently, two
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virus vectors were unilaterally injected into the rat substantia nigra
pars compacta [19]. Quite surprisingly, this administration was
found to cause a significant loss of nigrostriatal dopaminergic
neurons. In the present study, the effects of siRNA directed against
a-synuclein were tested in the monkey substantia nigra. Several
lines of consideration underscore the relevance of this work. To
the best of our knowledge, no study to date has assessed the
feasibility, effectiveness and safety of RNAi-based suppression of a-
synuclein in the primate brain. Moreover, the apparent inconsis-
tency of rodent data warrants further evaluation in an animal
model highly pertinent to humans. Finally, investigations using
monkey models are justified by a-synuclein features unique to the
primate brain (e.g. age-related upregulation) that may contribute
to pathogenetic processes [20–22]. siRNA directed against a-
synuclein was continuously infused into the substantia nigra of
squirrel monkeys over a one-month period. Post-mortem evalu-
ation determined if this treatment decreased neuronal expression
of both a-synuclein mRNA and protein, and if it was associated
with inflammatory tissue reaction. The number of nigral
dopaminergic neurons and the concentration of striatal dopamine
were also assayed to rule out any adverse effect of a-synuclein
siRNA on dopaminergic cell function/integrity.
Methods
Ethics Statement
Monkeys were housed at The Parkinson’s Institute in a facility
constructed according to AAALAC guidelines. Animal welfare
and experimental protocols were in accordance with the guidelines
of the National Institutes of Health and the Office of the
Prevention of Research Risks and were approved by the
Institutional Animal Care and Use Committee at The Parkinson’s
Institute. Monkeys had free access to water and a daily diet of
monkey chow and fresh fruit. They were evaluated weekly for
general health (e.g. weight) and, if necessary, treated by an
attending Veterinarian. During the surgical procedure, monkeys
were anesthetized with ketamine and isoflurane. To prevent post-
surgery pain/discomfort, animals were treated with an analgesic
drug for at least 24 hours. After surgery, they were also assessed
daily for weight, food consumption, general health and appear-
ance, and urine and fecal output. Monitoring of these parameters
revealed no significant post-surgery side effects. The animals were
euthanized using procedures consistent with the recommendations
of the Panel of Euthanasia of the American Veterinary Medical
Association.
Sequencing
Total RNA was isolated from cerebellar tissue from 20 squirrel
monkeys, and cDNA prepared using SuperScript III First Strand
Synthesis kit (Invitrogen, Carlsbad, CA). PCR primers were
designed (forward 59-CGACGACAGTGTGGTGTAAA-39 and
reverse 59-GCACATTGGAACTGAGCACT-39) to amplify the
entire SNCA gene. Standard PCR reactions were performed using
Qiagen PCR reagents (Qiagen, Valencia, CA) and a 60-50uC
touchdown PCR protocol. Reactions contained a final concen-
tration of 0.8 mM of each primer, 1 unit of Taq polymerase and
5 ml of Q solution (Qiagen). PCR products were purified using
AMPure (Agencourt Biosciences, Beverly, MA) and then
sequenced in both directions using the Big Dye Terminator v3.1
Cycle Sequencing kit (Applied Biosystems, Carlsbad, CA).
Sequencing reactions were purified using CleanSEQ (Agencourt
Biosciences) and analyzed on an ABI3730 Genetic Analyzer
(Applied Biosystems).
Animal Procedures and Tissue Preparation
A total of 6 feral adult squirrel monkeys (Saimiri scuireus) of both
sexes (4 females and 2 males) were purchased from Worldwide
Primates (Miami, FL) and underwent stereotactic surgery. A
cannula (20 mm length, 0.18 mm internal diameter and 0.36 mm
outer diameter, Plastics One, Roanoke, VA) was implanted
(18.7 mm deep) into the left midbrain at the following co-
ordinates: +4.75 mm anterior and +2.0 mm lateral to bregma
[23]. An Alzet osmotic mini-pump (2004 model, Durect Inc.,
Cupertino, CA) containing siRNA solution (27 mg/ml in 0.1 M
phosphate buffered saline, pH 7.4) was attached to the cannula via
catheter tubing and placed under the skin in the mid-scapular
region. Pumps delivered the siRNA into the left substantia nigra
for a 4-week period at a flow rate of 5.4 mg/hour.
Four weeks after cannula implantation, the animals were
euthanized, and their brains were rapidly removed and dissected.
A tissue block encompassing the entire substantia nigra from each
hemisphere was prepared and fixed in 4% paraformaldehyde in
phosphate buffered saline, cryoprotected and frozen. Each block
was cryostat-cut into 40 mm-thick sections. The two cerebral
hemispheres were cut into 2 mm-thick serial sections using a brain
mold and snap-frozen.
In situ Hybridization
a-Synuclein RNA probes labeled with digoxigenin (dig-11-
UTP, Roche Applied BioSciences, Indianapolis, IN) were
prepared by in vitro transcription using T7 RNA polymerases
(Ambion, Austin, TX) [24]. Midbrain sections from both
hemispheres were processed in parallel and incubated overnight
at 60uC with either antisense or sense probes. Hybridization signal
was detected using an anti-digoxigenin antibody, 5-bromo-4-
chloroindolyl-phosphatase and nitroblue tetrazolium (Roche
Applied Biosciences).
Quantitative PCR
The substantia nigra was dissected from 40 mm cryostat-cut
midbrain sections. Total RNA was extracted using RNeasy FFPE
kit (Qiagen) and reverse-transcribed in the presence of a random
hexamer primer into cDNA (SuperScript III first-strand synthesis
for reverse transcription PCR kit, Invitrogen). The resulting cDNA
sample was diluted and used as template DNAfor quantitative PCR
(qPCR) reactions (PRISM 7000 sequence detection system, Applied
Biosystems).Data werenormalized tob-actincontent andexpressed
as fold change over a control sample from the right (untreated)
substantianigra. Two gene-specific primer sequences were designed
with Primer Express software (Applied Biosystems) based on the
human a-synuclein sequence (GenBank: BC013293.2). To ensure
reliability of the results, analyses were performed using two separate
sets of primers. The first set was: 59-AAGGACCAGTTGGGCAA-
GAATG-39 and59-TGCCTGTGGATCCTGACAATGA-39. The
second set was: 59- AAAGGACCAGTTGGGCAAG -39 and 59-
TCCAGAATTCCTTCCTGTGG-39. For b-actin, the primers
used were 59-CAGCAGATGTGGATCAGCAAG-39 and 59-
GCATTTGCGGTGGACGAT-39 [25]. The absence of unwanted
by-products was confirmed by automated melting-curve analysis
and agarose gel electrophoresis.
Stereology and Immunohistochemistry
All quantitative analyses were performed by an investigator
blinded to the animal treatment. Stereological cell counting was
carried out as previously described [26]. Briefly, every twelfth
section throughout the substantia nigra (8–9 sections per
hemisphere) was immunostained with an anti-tyrosine hydroxylase
a-Synuclein siRNA in Monkeys
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biotin immunoperoxidase method (Vector, Burlingame, CA) with
3,39-diaminobenzidine (DAB) as the chromagen. Sections were
counterstained with cresyl violet and the number of dopaminergic
neurons counted using the optical fractionator technique (Stereo-
Investigator, MBF Bioscience, Williston, VT). The substantia
nigra was delineated at low magnification on each section. It was
then systematically sampled with a 1006oil immersion lens using
the nucleolus as the sampling unit. Dopaminergic neurons were
identified by the presence of TH immunoreactivity and/or
neuromelanin pigmentation [26]. The coefficient of error ranged
between 0.08 and 0.09.
Two midbrain sections per hemisphere were used for
densitometric quantification of nigral a-synuclein immunoreactiv-
ity. Sections were immersed in 5% normal serum prior to
incubation in mouse-anti-a-synuclein (1:6,000; LabVision, Fre-
mont, CA). Immunostaining was detected using the avidin-biotin
immunoperoxidase method with DAB as the chromagen. The
right and left substantia nigra were delineated at low magnification
and then systematically sampled using a 1006oil immersion lens.
A grid size of 3806810 um
2 was used to generate approximately
15 evenly spaced nigral sampling areas per hemisphere. Digital
images of these areas were acquired using a camera system
attached to an Olympus BX51 microscope. They were then
analyzed with SimplePCI software (Compix Inc., Lake Oswego,
OR) to determine the optical density of a-synuclein immunore-
activity. All parameters, such as light intensity, were standardized
and kept consistent throughout the analysis. For each animal,
optical densities of the sampling areas from the right or left
hemisphere were averaged.
For visualization of microglia, midbrain sections were immuno-
stained with an antibody recognizing the microglial marker ionizing
calcium-binding adaptor molecule 1 (Iba-1) (1:1,000; Biocare
Medical, Concord, CA) and counterstained with cresyl violet. To
assess whether cannula implantation and/or siRNA infusion caused
microglial changes, the number of Iba-1-positive cells with
morphologicalfeaturesofrestingoractivated microgliawascounted
in the substantia nigra. For each animal, counts were performed on
two sections collected at the site of the exit of the cannula in the left
hemisphere or at the corresponding anatomical level on the right
side. Values from the two sections were then averaged.
Neurochemical Measurements
For each monkey, four tissue punches (approximately 5 mg
each) were collected from the caudate (lateral and medial) and
putamen (ventral and dorsal) at the level of the anterior
commissure. After immediate sonication in 0.4 N perchloric acid,
sample homogenates were centrifuged at 15,0006g for 12 min at
4uC. Protein levels were assayed in the pellets, while supernatants
were used for measurements of dopamine, dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA) by HPLC coupled to
electrochemical detection [26].
Statistical Analysis
Data are presented as mean 6 SEM. Paired Student’s t-test was
performed to compare values obtained from the right (untreated)
vs. left (siRNA-infused) substantia nigra. P,0.05 was considered a
significant difference.
Results
Effect of siRNA Infusion on Nigral a-Synuclein Expression
DNA was extracted from cerebellar samples of squirrel monkeys
and used to deduce the nucleotide sequence of the a-synuclein
gene (SNCA). A 21-base pair siRNA duplex was designed and
synthesized to specifically target the squirrel monkey SNCA
transcript; oligonucleotides were chemically modified to prevent
degradation by exo- and endonucleases (Fig. 1A). Three monkeys
(2 females and one male) were treated with this a-synuclein
siRNA. The siRNA was infused unilaterally for a period of 4 weeks
via a cannula implanted approximately 1 mm dorsal to the left
substantia nigra and connected to an Alzet mini-pump (Fig. 1B).
To rule out the possibility of non-specific effects of siRNA infusion,
a separate group of 3 monkeys (2 females and one male) received a
4-week nigral infusion with control siRNA targeting a futile
protein, i.e. firefly luciferase.
Post-mortem analysis assessed the effect of siRNA adminis-
tration on a-synuclein mRNA by both in situ hybridization and
qPCR. a-Synuclein in situ hybridization was performed on a set
of midbrain sections at the level of the exit of the 3
rd nerve
encompassing the mid substantia nigra. Sections from the left
(siRNA-infused) and right (untreated) hemispheres, which were
processed in parallel, showed an overt difference in mRNA
labeling, with less robust signal intensity and decreased
number of labeled neurons in the left substantia nigra of all
3 animals receiving a-synuclein siRNA (Fig. 2A). In contrast,
no apparent change in hybridization signal was detected
between the left and right side of the brain in the 3 monkeys
infused with luciferase siRNA (Fig. 2B). Nigral dopaminergic
neurons in the primate brain can be identified due to their
content of neuromelanin pigment [26]. Higher magnification
images of right midbrain sections labeled for a-synuclein
mRNA showed a robust signal within neuromelanin-loaded
cells (Fig. 3A). The intensity of this signal was markedly
Figure 1. Treatment of squirrel monkeys with siRNA. Animals
were unilaterally implanted with a cannula connected to an Alzet
minipump delivering siRNA into the left substantia nigra. (A) Sequence
of the a-synuclein siRNA. ‘‘A,C,G,U’’ indicate ribonucleotides, ‘‘T’’
designates deoxythymidine, ‘‘c’’ and ‘‘u’’ specify 29-O-Me-modified
pyrimidines and ‘‘s’’ denotes a phosphorothioate linkage. (B) Midbrain
sections were immunostained for tyrosine hydroxylase (brown) and
counterstained with cresyl violet (purple). A representative section
shows placement of the cannula approximately 1 mm dorsal to the
substantia nigra (SN). The location of the cannula is indicated by the
square box, and the asterisk denotes the exit of the third nerve. Scale
bar=800 mm.
doi:10.1371/journal.pone.0012122.g001
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hemisphere (Fig. 3B), consistent with the interpretation that
suppression of a-synuclein mRNA occurred within the cell
body of nigral dopaminergic neurons.
Quantitative PCR was used to measure changes in a-synuclein
mRNA caused by siRNA administration. For each monkey,
samples of the left (siRNA-infused) and right (untreated) substantia
nigra were dissected from two midbrain sections, one anterior and
one posterior to the third nerve. RNA was extracted from these
samples, and analyses compared the effects of siRNA infusion
between the two hemispheres as well as in the rostral and caudal
portions of the substantia nigra. Treatment with a-synuclein but
not luciferase siRNA caused a significant reduction of a-synuclein
expression, as reflected by a decrease in the left:right mRNA ratio
(paired Student’s t test, P=0.03; Fig. 4). Within the left
hemisphere, the extent of this effect was 50% in the anterior
Figure 2. Reduction of a-synuclein mRNA in the substantia nigra infused with a-synuclein siRNA. Squirrel monkeys received a unilateral
nigral infusion of siRNA targeting a-synuclein (A) or luciferase (B). Midbrain sections at the level of the exit of the 3
rd nerve were used for a-synuclein
in situ hybridization using digoxigenin-labeled antisense riboprobes. Representative images compare a-synuclein mRNA in the right (untreated) vs.
left (siRNA-infused) substantia nigra. Scale bar=100 mm.
doi:10.1371/journal.pone.0012122.g002
Figure 3. a-Synuclein siRNA decreases a-synuclein mRNA within pigmented nigral neurons. siRNA against a-synuclein was infused into
the left substantia nigra of squirrel monkeys. Right (A) and left (B) midbrain sections at the level of the exit of the 3
rd nerve were used for a-synuclein
in situ hybridization. Representative images show nigral dopaminergic neurons containing neuromelanin (brown granules). The hybridization signal
(purple) was markedly reduced in the left (siRNA-infused) as compared to the right (untreated) hemisphere. Scale bar=10 mm.
doi:10.1371/journal.pone.0012122.g003
a-Synuclein siRNA in Monkeys
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12122and 42% in the posterior substantia nigra (not statistically
different; Fig. 4A).
siRNA-induced changes in a-synuclein protein were assessed by
immunohistochemistry. Features of a-synuclein distribution have
been previously characterized in the monkey substantia nigra: a-
synuclein immunoreactivity labels the neuropil in a punctate
pattern, with little or no staining of neuronal cell bodies [22]. We
confirmed this pattern and showed marked a-synuclein immuno-
reactivity in midbrain sections from the right hemisphere (Fig. 5A).
This immunoreactivity was decreased in all 3 monkeys infused
with a-synuclein siRNA (Fig. 5B); indeed, densitometric analysis
revealed a significant 40% difference between the siRNA-infused
(left) and untreated (right) substantia nigra (Fig. 5C). In contrast,
no change in a-synuclein staining was observed as a consequence
of luciferase siRNA administration (data not shown).
Lack of Adverse Effects of a-Synuclein siRNA Infusion
A variety of markers of systemic toxicity (e.g., animal’s weight
and temperature) were monitored throughout the course of the
experiments. No complications or adverse effects were observed
during surgical procedure, post-operative recovery/treatment and
time of infusion. Post-mortem analysis of midbrain sections
revealed that a-synuclein siRNA infusion did not cause overt
tissue inflammation in the form of microglial activation. After
staining with Iba-1, resting and activated microglial cells were
identified and counted based on their morphological characteris-
tics. Within the substantia nigra, the vast majority of Iba-1-
immunoreactive cells featured small bodies and thin ramifications
reminiscent of resting microglia; their number was unchanged
between the two hemispheres (Fig. 6A–E). Microglial cells with
amoeboid-shaped cytoplasm and thick, short ramifications were
present around the cannula tract (Fig. 6F). These activated cells
were rarely observed, however, within the nearby parenchyma as
well as in sections throughout the left (siRNA-infused) and right
(untreated) midbrain.
To rule out neuronal damage as a consequence siRNA infusion,
the number of dopaminergic cells was counted in the right and left
substantia nigra of monkeys receiving unilateral infusion of a-
synuclein siRNA. The number of TH-immunoreactive neurons,
which was estimated using stereological methods, was found to be
approximately 53,000 and not significantly different between the
two hemispheres (Fig. 7). Data from earlier reports indicate that
TH-based counting does not identify all dopaminergic neurons in
the monkey substantia nigra; a subpopulation of these cells is
devoid of TH immunoreactivity but can still be recognized by
their neuromelanin load [26]. We therefore counted these
additional cells and calculated the total number of dopaminergic
neurons by adding the number of TH-positive cells plus the
number of neuromelanin-containing (TH-negative) neurons.
Consistent with previous results [24,26], this total count was
approximately 60,000 in the right and left hemispheres, indicating
that infusion with a-synuclein siRNA affected neither the number
nor the phenotype (i.e. TH-positive vs. TH-negative) of nigral
neurons (Fig. 7).
A final set of measurements was carried out in samples from the
monkey caudate and putamen to determine if a-synuclein
Figure 4. Measurement of nigral a-synuclein mRNA by qPCR.
Squirrel monkeys received unilateral nigral infusion of siRNA targeting
a-synuclein (A) or luciferase (B). Nigral tissue was dissected from
midbrain sections rostral and caudal to the exit of the 3
rd nerve. Values
are the ratio of a-synuclein mRNA levels measured by qPCR in the left
(siRNA-infused) and right (untreated) substantia nigra (L:R ratio). Bars
represent mean values.
doi:10.1371/journal.pone.0012122.g004
Figure 5. Effect of a-synuclein siRNA on a-synuclein protein in
the monkey substantia nigra. a-Synuclein or luciferase siRNA was
unilaterally infused into the left substantia nigra. Midbrain sections
were immunostained with an antibody against a-synuclein. Represen-
tative images from an animal receiving a-synuclein siRNA show more
robust a-synuclein immunoreactivity within the neuropil of the right
(untreated, A) vs. left (siRNA-infused, B) substantia nigra. Scale
bar=5 mm. (C) Optical density measurements of nigral a-synuclein
immunoreactivity. Data are expressed as percent of the control value in
the right (untreated) substantia nigra and represent mean 6 SEM. A
significant decrease is caused by a-synuclein but not luciferase siRNA in
the left (siRNA-infused) hemisphere. *p,0.03.
doi:10.1371/journal.pone.0012122.g005
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its metabolites DOPAC and HVA. Unilateral administration of a-
synuclein siRNA did not cause any significant neurochemical
alteration; dopamine, DOPAC and HVA levels were similar in the
right and left striatum (Table 1).
Discussion
Results of this study provide the first documentation that a-
synuclein expression can be significantly reduced via RNAi in the
primate brain. siRNA targeting a-synuclein suppressed both a-
synuclein mRNA and protein. The selectivity of this effect was
demonstrated by experiments in which monkeys were treated with
luciferase rather than a-synuclein siRNA. Lack of changes in the
brain of these control animals underscores that a-synuclein
silencing requires administration of SNCA-complementary siRNA.
Data also reveal that siRNA directed against a-synuclein is
capable of decreasing its expression within neuronal cells highly
susceptible to neurodegenerative processes, i.e. nigrostriatal
dopaminergic neurons. siRNA-induced reduction of a-synuclein
mRNA was observed in midbrain sections encompassing the
rostral, mid- and caudal substantia nigra. This finding indicates
that the infusion protocol of naked siRNA employed in this study
was effective in lowering a-synuclein throughout the monkey
substantia nigra.
Our present data show a 40–50% reduction of nigral a-
synuclein. Based on in vitro and in vivo evidence [16,19], more
pronounced a-synuclein suppression could conceivably be
achieved by increasing the dosage of siRNA, testing other siRNA
molecules or using a different method for siRNA delivery (e.g. viral
vector). Further studies should confirm this concept in the primate
substantia nigra. Additional work is also warranted to confirm and
extend data in rodents indicating that a-synuclein silencing is
sustained even after cessation of siRNA treatment; when a-
synuclein siRNA was infused into the rat hippocampus, levels of a-
synuclein mRNA returned to normal levels by three weeks post-
infusion [18].
Although more powerful siRNA molecules could be evaluated
in our animal model to achieve a greater reduction of neuronal a-
Figure 6. Lack of microglial activation following siRNA
infusion. a-Synuclein siRNA was unilaterally infused through a cannula
positioned approximately 1 mm dorsal to the substantia nigra.
Representative midbrain sections were immunostained for microglial
cells using an antibody against ionizing calcium-binding adaptor
molecule 1 (Iba-1, brown) and counterstained with cresyl violet
(purple). Images are from the right (untreated, A and C) and left
(siRNA-infused, B and D) substantia nigra. At higher magnification (C
and D), Iba-1-positive cells with morphological features of resting
microglia are shown close to dopaminergic neurons containing
neuromelanin (black granules). The arrows indicate one of these
neurons in each panel. Scale bars=20 mm (A and B) and 10 mm (C and
D). (E) The number of Iba-1-immunoreactive cells was counted in the
right (R) and left (L) substantia nigra. Data are shown as mean 6 SEM.
(F) A representative section from the left midbrain shows Iba-1
immunoreactivity close to the tip of the infusion cannula (arrow) but
not within the nearby parenchyma. This robust immunoreactivity was
observed within cells with morphological characteristics of activated
microglia (inset). Scale bars=250 mm (panel F) and 10 mm (inset).
doi:10.1371/journal.pone.0012122.g006
Figure 7. The number of nigral dopaminergic neurons is not
affected by siRNA-induced a-synuclein suppression. Squirrel
monkeys received a unilateral nigral infusion of siRNA targeting a-
synuclein. Both the number of TH-immunoreactive cells and the total
number of dopaminergic neurons were counted stereologically in the
substantia nigra. Values (mean 6 SEM) were not different between the
right (untreated) and left (siRNA-infused) hemisphere.
doi:10.1371/journal.pone.0012122.g007
Table 1. Levels of striatal dopamine, DOPAC and HVA are
unaffected by a-synuclein siRNA infusion.
Region Dopamine DOPAC HVA
Right Left Right Left Right Left
LC 142691 5 5 65 11.661.6 11.760.8 61.165.9 63.866.4
MC 158681 6 7 612 11.661.2 11.261.8 57.865.1 52.167.7
DP 174671 9 2 610 9.861.0 9.860.9 83.368.9 93.766.8
VP 158671 6 7 69 13.262.4 14.061.2 82.4615 90.6614
a-Synuclein siRNA was unilaterally infused into the left substantia nigra. Values
are expressed as ng/mg protein. Data are shown as mean 6 SEM. LC, lateral
caudate; MC, medial caudate; DP, dorsal putamen; VP, ventral putamen.
doi:10.1371/journal.pone.0012122.t001
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the present results. a-Synuclein is a relatively abundant protein
in the CNS where it is thought to play a role in synaptic
neurotransmission and plasticity and has been found to regulate
pathways involved in dopaminergic activity [27–29]. The dual
behavior of a-synuclein, involving both toxic and physiological
properties, has important implications for the development of anti-
a-synuclein therapeutics. Less-than-complete a-synuclein suppres-
sion, as achieved in our study, would be less likely to have a
negative impact on the normal function of the protein. This partial
effect could still be sufficient, however, to counteract a-synuclein’s
toxic potential and to avert conditions that have been implicated
in a-synuclein pathology. Deleterious properties such as the
tendency of a-synuclein to aggregate are concentration-dependent
and would be inhibited at lower protein expression [11].
Moreover, as a consequence of reduced a-synuclein burden,
neuronal mechanisms of protein homeostasis, such as proteasomal
and lysosomal degradation pathways [30–32], could more
effectively prevent a-synuclein-dependent pathology.
Another important corollary to the concept of a-synuclein
playing both a physiological and pathological role is that anti-a-
synuclein approaches need to be evaluated for possible adverse
consequences. Results of our present study are consistent with the
interpretation that siRNA-induced a-synuclein reduction is devoid
of overt side effects. Monkeys infused with a-synuclein siRNA
showed no signs of either systemic or tissue-specific toxicity. The
latter, as assessed in the form of lack of microglial activation, is
particularly relevant given that (i) nigral tissue is highly vulnerable
to inflammatory-mediated injury, and (ii) neuroinflammation is
thought to contribute to pathogenetic process in PD and other
neurodegenerative diseases [33,34]. Thus, one of the potential
benefits of treatment with naked siRNA as compared, for example,
to viral vector-mediated delivery of siRNA is a lack of tissue
reaction to the directly infused molecule.
Further supporting the safety of this treatment, the total number
of dopaminergic neurons was found to be unchanged in the
substantia nigra infused with a-synuclein siRNA. The count of
TH-immunoreactive cells was also unaffected, suggesting that a-
synuclein inhibition did not cause any marked loss of nigral TH
expression. Quite noteworthy are the results of measurements of
dopamine and its metabolites as markers of dopaminergic
function/integrity at the level of striatal terminals. In an earlier
investigation, alterations in electrically evoked dopamine release
were found using striatal slice preparations from mice lacking a-
synuclein [28]. These mutant animals were also characterized by a
significant decrease in striatal dopamine, suggesting a role of a-
synuclein in presynaptic regulation of dopaminergic neurotrans-
mission [28,35]. Dopamine concentrations were measured in our
study in the monkey caudate and putamen and values were
compared in the siRNA-infused (left) vs. untreated (right) side of
the brain. Results showed that a-synuclein suppression did not
affect striatal dopamine since levels of this neurotransmitter as well
as levels of its metabolites DOPAC and HVA were not different in
the left and right striatum. Several explanations could underlie the
apparent inconsistency between previous findings and the current
data, including the fact that experiments involved different animal
species (rodent vs. primates). Most likely, however, changes in
striatal dopamine may be dependent upon the extent and/or
duration of a-synuclein deficiency; no effect was observed after
partial and temporary a-synuclein reduction in our siRNA-treated
monkeys, whereas a dopamine loss resulted from lifelong ablation
of a-synuclein in mutant mice.
Similar considerations could apply to the evaluation of data
recently published indicating that viral vector-based RNAi
targeting a-synuclein in the rat substantia nigra caused dopami-
nergic cell loss and behavioral changes consistent with nigrostriatal
impairment [19]. These dramatic effects, which contrast with the
lack of overt toxicity in the present study, may further emphasize
the importance of partial vs. more pronounced silencing of a-
synuclein. Indeed, nigrostriatal damage was observed in rats in
which siRNA treatment resulted in .90% reduction of a-
synuclein mRNA [19]. Other important differences between the
earlier report and our present investigation concern the animal
species in which nigral a-synuclein was silenced and the method of
siRNA delivery, i.e. injection of an adeno-associated virus vector
vs. infusion of naked siRNA.
Taken together, the results of this study provide important new
evidence that RNAi-mediated suppression of a-synuclein in the
primate brain is feasible and relatively safe and should therefore be
further pursued for therapeutic purposes against human a-
synucleinopathies. Potential caveats include the extent and
duration of a-synuclein silencing. Would partial suppression be
sufficient to achieve neuroprotection and, if not, could a close-to-
complete reduction of a-synuclein pose safety risks? In the present
study, siRNA infusion was maintained over a period of one month.
However, treatment of chronic a-synucleinopathies will likely
involve long-term anti-a-synuclein intervention. Thus, detailed
evaluation of the consequences of protracted a-synuclein suppres-
sion is needed to confirm sustained siRNA efficacy and to rule out
the possibility that adverse side effects may become evident only
after prolonged silencing of a-synuclein expression.
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